{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:07:46Z","timestamp":1777122466959,"version":"3.51.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41440-025-02418-2","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T03:28:09Z","timestamp":1760585289000},"page":"3159-3171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight"],"prefix":"10.1038","volume":"48","author":[{"given":"Masami","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2418_CR1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19:201\u201316.","journal-title":"Nat Rev Endocrinol"},{"key":"2418_CR2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00125-017-4450-9","volume":"61","author":"T Jorsal","year":"2018","unstructured":"Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL, et al. Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia. 2018;61:284\u201394.","journal-title":"Diabetologia"},{"key":"2418_CR3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","volume":"63","author":"MA Nauck","year":"1986","unstructured":"Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"2418_CR4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409\u201339.","journal-title":"Physiol Rev"},{"key":"2418_CR5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","volume":"14","author":"A Andersen","year":"2018","unstructured":"Andersen A, Lund A, Knop FK, Vilsb\u00f8ll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14:390\u2013403.","journal-title":"Nat Rev Endocrinol"},{"key":"2418_CR6","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2418_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11906-015-0621-6","volume":"18","author":"A Goud","year":"2016","unstructured":"Goud A, Zhong J, Peters M, Brook RD, Rajagopalan S. GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016;18:16.","journal-title":"Curr Hypertens Rep"},{"key":"2418_CR8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15:737\u201349.","journal-title":"Diabetes Obes Metab"},{"key":"2418_CR9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/ajh.2009.245","volume":"23","author":"T Okerson","year":"2010","unstructured":"Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23:334\u20139.","journal-title":"Am J Hypertens"},{"key":"2418_CR10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1742-1241.2009.02265.x","volume":"64","author":"B Gallwitz","year":"2010","unstructured":"Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pr. 2010;64:267\u201376.","journal-title":"Int J Clin Pr"},{"key":"2418_CR11","doi-asserted-by":"crossref","unstructured":"Robinson LE, Holt TA, Rees K, Randeva HS, O\u2019Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:e001986.","DOI":"10.1136\/bmjopen-2012-001986"},{"key":"2418_CR12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajh\/hpt196","volume":"27","author":"M Katout","year":"2014","unstructured":"Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27:130\u20139.","journal-title":"Am J Hypertens"},{"key":"2418_CR13","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/s41440-023-01324-9","volume":"46","author":"K Sawami","year":"2023","unstructured":"Sawami K, Tanaka A, Node K. Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?. Hypertens Res. 2023;46:1892\u20139.","journal-title":"Hypertens Res"},{"key":"2418_CR14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11695-008-9671-z","volume":"19","author":"AR Ahmed","year":"2009","unstructured":"Ahmed AR, Rickards G, Coniglio D, Xia Y, Johnson J, Boss T, et al. Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure. Obes Surg. 2009;19:845\u20139.","journal-title":"Obes Surg"},{"key":"2418_CR15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11906-019-0964-5","volume":"21","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Itoh H. Hypertension as a metabolic disorder and the novel role of the gut. Curr Hypertens Rep. 2019;21:63.","journal-title":"Curr Hypertens Rep"},{"key":"2418_CR16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/ijo.2010.132","volume":"35","author":"CN Ochner","year":"2011","unstructured":"Ochner CN, Gibson C, Shanik M, Goel V, Geliebter A. Changes in neurohormonal gut peptides following bariatric surgery. Int J Obes. 2011;35:153\u201366.","journal-title":"Int J Obes"},{"key":"2418_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab"},{"key":"2418_CR18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","volume":"22","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Mosenzon O, Brown K, Cui X, O\u2019Neill C, Fern\u00e1ndez Land\u00f3 L, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22:66.","journal-title":"Cardiovasc Diabetol"},{"key":"2418_CR19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1?. Trends Endocrinol Metab. 2020;31:410\u201321.","journal-title":"Trends Endocrinol Metab"},{"key":"2418_CR20","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","volume":"133","author":"TB Usdin","year":"1993","unstructured":"Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993;133:2861\u201370.","journal-title":"Endocrinology"},{"key":"2418_CR21","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/endo.134.5.8156917","volume":"134","author":"RV Campos","year":"1994","unstructured":"Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology. 1994;134:2156\u201364.","journal-title":"Endocrinology"},{"key":"2418_CR22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0303-7207(98)00096-3","volume":"141","author":"JL Dunphy","year":"1998","unstructured":"Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol. 1998;141:179\u201386.","journal-title":"Mol Cell Endocrinol"},{"key":"2418_CR23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24:15\u201330.","journal-title":"Cell Metab"},{"key":"2418_CR24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","volume":"54","author":"AK Bose","year":"2005","unstructured":"Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes. 2005;54:146\u201351.","journal-title":"Diabetes"},{"key":"2418_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13:605\u201328.","journal-title":"Nat Rev Nephrol"},{"key":"2418_CR26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","volume":"15","author":"J Skov","year":"2014","unstructured":"Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15:197\u2013207.","journal-title":"Rev Endocr Metab Disord"},{"key":"2418_CR27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrneph.2013.272","volume":"10","author":"MH Muskiet","year":"2014","unstructured":"Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. Nat Rev Nephrol. 2014;10:88\u2013103.","journal-title":"Nat Rev Nephrol"},{"key":"2418_CR28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","volume":"38","author":"A Wettergren","year":"1993","unstructured":"Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38:665\u201373.","journal-title":"Dig Dis Sci"},{"key":"2418_CR29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, J\u00f3dar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45:409\u201318.","journal-title":"Diabetes Metab"},{"key":"2418_CR30","doi-asserted-by":"crossref","unstructured":"Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. J Clin Med. 2023;12:772.","DOI":"10.3390\/jcm12030772"},{"key":"2418_CR31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143\u201355.","journal-title":"Lancet"},{"key":"2418_CR32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"2418_CR33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583\u201398.","journal-title":"Lancet"},{"key":"2418_CR34","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811\u201324.","journal-title":"Lancet"},{"key":"2418_CR35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327:534\u201345.","journal-title":"JAMA"},{"key":"2418_CR36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","volume":"83","author":"W Wu","year":"2024","unstructured":"Wu W, Tong HM, Li YS, Cui J. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine. 2024;83:571\u201384.","journal-title":"Endocrine"},{"key":"2418_CR37","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23:2116\u201324.","journal-title":"Diabetes Obes Metab"},{"key":"2418_CR38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-016-0155-1","volume":"7","author":"S Kayaniyil","year":"2016","unstructured":"Kayaniyil S, Lozano-Ortega G, Bennett HA, Johnsson K, Shaunik A, Grandy S, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Ther. 2016;7:27\u201343.","journal-title":"Diabetes Ther"},{"key":"2418_CR39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"2418_CR40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12933-023-01775-x","volume":"22","author":"KC Ferdinand","year":"2023","unstructured":"Ferdinand KC, Dunn J, Nicolay C, Sam F, Blue EK, Wang H. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22:49.","journal-title":"Cardiovasc Diabetol"},{"key":"2418_CR41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","volume":"28","author":"VA Fonseca","year":"2014","unstructured":"Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28:399\u2013405.","journal-title":"J Diabetes Complications"},{"key":"2418_CR42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731\u20137.","journal-title":"Hypertension"},{"key":"2418_CR43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39\u201350.","journal-title":"Lancet"},{"key":"2418_CR44","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1152\/ajpendo.00429.2014","volume":"308","author":"A Asmar","year":"2015","unstructured":"Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, et al. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab. 2015;308:E641\u20139.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2418_CR45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/EJE-16-0507","volume":"176","author":"MM Smits","year":"2017","unstructured":"Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, et al. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. Eur J Endocrinol. 2017;176:77\u201386.","journal-title":"Eur J Endocrinol"},{"key":"2418_CR46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","volume":"18","author":"J Skov","year":"2016","unstructured":"Skov J, Pedersen M, Holst JJ, Madsen B, Goetze JP, Rittig S, et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab. 2016;18:581\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2418_CR47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2012.04214.x","volume":"74","author":"B Mendis","year":"2012","unstructured":"Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharm. 2012;74:437\u201344.","journal-title":"Br J Clin Pharm"},{"key":"2418_CR48","doi-asserted-by":"crossref","unstructured":"Bremholm L, Andersen UB, Hornum M, Hilsted L, Veedfald S, Hartmann B, et al. Acute effects of glucagon-like peptide-1, GLP-1(9-36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers. Physiol Rep. 2017;5:e13102.","DOI":"10.14814\/phy2.13102"},{"key":"2418_CR49","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","volume":"98","author":"J Skov","year":"2013","unstructured":"Skov J, Dejgaard A, Fr\u00f8ki\u00e6r J, Holst JJ, Jonassen T, Rittig S, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013;98:E664\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"2418_CR50","doi-asserted-by":"crossref","first-page":"E744","DOI":"10.1152\/ajpendo.00518.2015","volume":"310","author":"A Asmar","year":"2016","unstructured":"Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, et al. Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. Am J Physiol Endocrinol Metab. 2016;310:E744\u201353.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2418_CR51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","volume":"38","author":"JA Lovshin","year":"2015","unstructured":"Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38:132\u20139.","journal-title":"Diabetes Care"},{"key":"2418_CR52","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke C, Heller RS, Kirk RK, \u00d8rskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280\u201390.","journal-title":"Endocrinology"},{"key":"2418_CR53","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","volume":"120","author":"AF Lubberding","year":"2024","unstructured":"Lubberding AF, Veedfald S, Achter JS, Nissen SD, Soattin L, Sorrentino A, et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res. 2024;120:1427\u201341.","journal-title":"Cardiovasc Res"},{"key":"2418_CR54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000183252","volume":"37","author":"K Thomsen","year":"1984","unstructured":"Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron. 1984;37:217\u201323.","journal-title":"Nephron"},{"key":"2418_CR55","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2022.100169","volume":"13","author":"H Itoh","year":"2022","unstructured":"Itoh H, Tanaka M. Greedy Organs Hypothesis\u201d for sugar and salt in the pathophysiology of non-communicable diseases in relation to sodium-glucose co-transporters in the intestines and the kidney. Metabol Open. 2022;13:100169.","journal-title":"Metabol Open"},{"key":"2418_CR56","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","volume":"89","author":"JP Gutzwiller","year":"2004","unstructured":"Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89:3055\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"2418_CR57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109\u201321.","journal-title":"N Engl J Med"},{"key":"2418_CR58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1291\/hypres.26.515","volume":"26","author":"H Makino","year":"2003","unstructured":"Makino H, Nakamura Y, Wada J. Remission and regression of diabetic nephropathy. Hypertens Res. 2003;26:515\u20139.","journal-title":"Hypertens Res"},{"key":"2418_CR59","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1152\/ajpendo.00373.2007","volume":"293","author":"A Basu","year":"2007","unstructured":"Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293:E1289\u201395.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2418_CR60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","volume":"19","author":"M Kim","year":"2013","unstructured":"Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567\u201375.","journal-title":"Nat Med"},{"key":"2418_CR61","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","volume":"303","author":"T Rieg","year":"2012","unstructured":"Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Ren Physiol. 2012;303:F963\u201371.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2418_CR62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/HYPERTENSIONAHA.120.14868","volume":"76","author":"FL Martins","year":"2020","unstructured":"Martins FL, Bailey MA, Girardi ACC. Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na(+)\/H(+) exchanger isoform 3, renal angiotensin II, and insulin sensitivity. Hypertension. 2020;76:839\u201348.","journal-title":"Hypertension"},{"key":"2418_CR63","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1210\/en.2013-1096","volume":"154","author":"AR Aroor","year":"2013","unstructured":"Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology. 2013;154:2501\u201313.","journal-title":"Endocrinology"},{"key":"2418_CR64","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","volume":"301","author":"RO Crajoinas","year":"2011","unstructured":"Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Ren Physiol. 2011;301:F355\u201363.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2418_CR65","doi-asserted-by":"crossref","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","volume":"297","author":"LR Carraro-Lacroix","year":"2009","unstructured":"Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na+\/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Ren Physiol. 2009;297:F1647\u201355.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2418_CR66","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41440-018-0070-0","volume":"41","author":"R Rodriguez","year":"2018","unstructured":"Rodriguez R, Moreno M, Lee AY, Godoy-Lugo JA, Nakano D, Nishiyama A, et al. Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats. Hypertens Res. 2018;41:798\u2013808.","journal-title":"Hypertens Res"},{"key":"2418_CR67","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41440-018-0085-6","volume":"41","author":"K Tamura","year":"2018","unstructured":"Tamura K, Yamaji T, Yamada T, Ohsawa M, Wakui H. An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity. Hypertens Res. 2018;41:784\u20136.","journal-title":"Hypertens Res"},{"key":"2418_CR68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2840-13-36","volume":"13","author":"CJ Li","year":"2014","unstructured":"Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:36.","journal-title":"Cardiovasc Diabetol"},{"key":"2418_CR69","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/HJH.0000000000000573","volume":"33","author":"S Haufe","year":"2015","unstructured":"Haufe S, Kaminski J, Utz W, Haas V, M\u00e4hler A, Daniels MA, et al. Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. J Hypertens. 2015;33:1458\u201364.","journal-title":"J Hypertens"},{"key":"2418_CR70","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.738848","volume":"12","author":"S Puglisi","year":"2021","unstructured":"Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol. 2021;12:738848.","journal-title":"Front Endocrinol"},{"key":"2418_CR71","doi-asserted-by":"crossref","first-page":"C768","DOI":"10.1152\/ajpcell.00191.2016","volume":"311","author":"RO Crajoinas","year":"2016","unstructured":"Crajoinas RO, Polidoro JZ, Carneiro de Morais CP, Castelo-Branco RC, Girardi AC. Angiotensin II counteracts the effects of cAMP\/PKA on NHE3 activity and phosphorylation in proximal tubule cells. Am J Physiol Cell Physiol. 2016;311:C768\u2013c76.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2418_CR72","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1523-1755.2003.00189.x","volume":"64","author":"D du Cheyron","year":"2003","unstructured":"du Cheyron D, Chalumeau C, Defontaine N, Klein C, Kellermann O, Paillard M, et al. Angiotensin II stimulates NHE3 activity by exocytic insertion of the transporter: role of PI 3-kinase. Kidney Int. 2003;64:939\u201349.","journal-title":"Kidney Int"},{"key":"2418_CR73","doi-asserted-by":"crossref","first-page":"H2376","DOI":"10.1152\/ajpheart.00614.2005","volume":"290","author":"XP Zhang","year":"2006","unstructured":"Zhang XP, Hintze TH. cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am J Physiol Heart Circ Physiol. 2006;290:H2376\u201384.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2418_CR74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.regpep.2004.08.024","volume":"125","author":"T Nystr\u00f6m","year":"2005","unstructured":"Nystr\u00f6m T, Gonon AT, Sj\u00f6holm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125:173\u20137.","journal-title":"Regul Pept"},{"key":"2418_CR75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","volume":"261","author":"T Jojima","year":"2017","unstructured":"Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis. 2017;261:44\u201351.","journal-title":"Atherosclerosis"},{"key":"2418_CR76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-55724-z","volume":"14","author":"M Wajdlich","year":"2024","unstructured":"Wajdlich M, Nowicki M. The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function. Sci Rep. 2024;14:5002.","journal-title":"Sci Rep"},{"key":"2418_CR77","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jch.14555","volume":"24","author":"K Kario","year":"2022","unstructured":"Kario K, Wang JG, Chia YC, Wang TD, Li Y, Siddique S, et al. The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. J Clin Hypertens. 2022;24:1112\u201320.","journal-title":"J Clin Hypertens"},{"key":"2418_CR78","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lfs.2014.03.029","volume":"104","author":"M Toyama","year":"2014","unstructured":"Toyama M, Watanabe S, Miyauchi T, Kuroda Y, Ojima E, Sato A, et al. Diabetes and obesity are significant risk factors for morning hypertension: from Ibaraki Hypertension Assessment Trial (I-HAT). Life Sci. 2014;104:32\u20137.","journal-title":"Life Sci"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02418-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:57Z","timestamp":1764889317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02418-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2418"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02418-2","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}